Pellinen T

Validation of fibroblast activation protein and α-smooth muscle actin as prognostic biomarkers in prostate cancer through AI-assisted image analysis of dual-marker IHC.

Säilä J, Lehto TP, Rannikko A, ..., Mirtti T, Pellinen T

J Pathol Clin Res 12 (1) e70068 [2026-01-00; online 2025-12-18]

Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.

Roos-Mattila M, Kallio P, Luck TJ, ..., Pietiäinen VM, Seppänen HE

Commun Biol 7 (1) 1355 [2024-10-20; online 2024-10-20]

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.

Murumägi A, Ungureanu D, Khan S, ..., Aittokallio T, Kallioniemi O

Br. J. Cancer 128 (4) 678-690 [2023-02-00; online 2022-12-07]

Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.

Pellinen T, Paavolainen L, Martín-Bernabé A, ..., Micke P, Östman A

J. Natl. Cancer Inst. 115 (1) 71-82 [2023-01-10; online 2022-09-10]

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

Bruun J, Eide PW, Bergsland CH, ..., Lothe RA, Pellinen T

Mol Oncol 16 (12) 2312-2329 [2022-06-00; online 2021-12-26]

Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer.

Pellinen T, Sandeman K, Blom S, ..., Rannikko A, Mirtti T

Cancer Res Commun 2 (3) 172-181 [2022-03-00; online 2022-03-21]

Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.

Blom S, Erickson A, Östman A, ..., Kallioniemi O, Pellinen T

Prostate 79 (13) 1505-1513 [2019-09-00; online 2019-07-03]

Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.

Slik K, Blom S, Turkki R, ..., Sundström J, Pellinen T

J Pathol Clin Res 5 (1) 63-78 [2019-01-00; online 2018-11-29]